Indications
Resmetirom tablets are used together with diet and exercise to treat adults who have noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, consistent with stages F2 to F3 fibrosis.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Resmetirom is a partial agonist of the thyroid hormone receptor-beta (THR-β). In an in vitro functional assay for THR-β activation, it produced 83.8% of the maximum response seen with triiodothyronine (T3), with an EC50 of 0.21 μM. The same kind of assay for thyroid hormone receptor alpha (THR-α) agonism showed 48.6% efficacy for resmetirom relative to T3, with an EC50 of 3.74 pM. THR-β is the major form of thyroid hormone receptor in the liver, and stimulating it there reduces intrahepatic triglycerides.
Pregnancy & Breastfeeding
Pregnancy
There are no data on the use of Resmetirom in pregnant women, so it isn't possible to say whether the medicine carries a risk of major birth defects, miscarriage, or other harmful outcomes for the mother or the baby.
Lactation
Nothing is known about whether Resmetirom passes into human or animal milk, what it might do to a breast-fed infant, or whether it affects milk production. A mother and her doctor should weigh the developmental and health benefits of breastfeeding against her clinical need for Resmetirom. They should also consider any possible harm to the breast-fed infant, either from Resmetirom or from the mother's own underlying condition.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.